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ABSTRACT
Introduction: The onset of inflammatory bowel disease (IBD) in children is rising. Current treatment
options are based on immunomodulatory therapy. Alternative treatment options are upcoming since
they appear to be effective in individual patients. Cannabis might relief IBD symptoms in these cases
and improve quality of life. Recent evidence suggests a potential anti-inflammatory effect of cannabis.
Areas covered: This review presents an overview of recent literature on the use of cannabis in IBD
focussing on pediatric IBD patients. Background information on the role of the endocannabinoid system
within the gastrointestinal tract is presented. Other modalities of cannabis and its purified ingredients
will be discussed as well, with attention to its applicability in children with IBD.
Expert opinion: More research is needed on the efficacy and safety of cannabis in pediatric IBD. Studies
are well underway, but until then the use of cannabis in pediatric IBD cannot be recommended.
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1. Introduction
The incidence of pediatric inflammatory bowel disease (IBD)
is steeply rising globally [1]. IBD includes Crohn’s disease
and ulcerative colitis, both diseases affect the gastroin
testinal tract by immune-mediated inflammation. These dis-
eases are characterized by relapsing and remitting episodes
of active disease, which may be accompanied by abdominal
pain, nausea, loss of appetite and diarrhea. The current
treatment options are based on the reduction of inflamma-
tory processes, by using immunomodulatory therapies, such
as corticosteroids, thiopurines, methotrexate and/or TNF-a
blockers. Despite the improvement in therapy, many IBD
patients report ongoing symptoms (abdominal pain, fati-
gue, poor appetite) with significant impact on quality of
life. Cannabis has been studied as an alternative treatment
to relief IBD symptoms. Over the past decades, cannabis or
also known as medical marijuana has gained more accep-
tance for conditions like chemotherapy-related nausea and
vomiting and chronic pain but also for spasticity and tremor
in neurological diseases. Cannabis may be promising in
improving the quality of life of IBD patients, by ameliorating
symptoms like: abdominal pain, nausea, diarrhea, and poor
appetite. Recent evidence suggests there also might be
a potential anti-inflammatory effect of cannabis on IBD dis-
ease activity. So cannabis is of high interest for this medical
condition.
Population-based surveys show that many adult and adoles-
cent IBD patients use cannabis to relieve abdominal symptoms
[2–6]. About 10 – 20 % of patients are still under the age of 18
years when diagnosed with IBD [1,7]. In this population, 32% of
the IBD patients use cannabis [8]. As a result, pediatric gastro-
enterologists will more frequently be confronted with patients
who will use cannabis to relieve IBD-related symptoms. There
fore, we conducted a review to summarize the present scientific
evidence about the efficacy and safety of cannabis in the treat-
ment of pediatric IBD.
For this review, a literature search was performed in Pubmed
and EMBASE on trials who evaluated the effect of cannabis on
IBD until September 2018. Keywords used were ‘inflammatory
bowel diseases,’ ‘Crohn disease,’ ‘Ulcerative colitis,’ ’Cannabis,’
‘Medical Marijuana,’ and ‘Cannabinoids.’
2. The endocannabinoid system and the
gastrointestinal tract
The effect of cannabis on the gastrointestinal tract is based
on involvement of the endocannabinoid system in gut func-
tioning. The endocannabinoid system contains receptors,
endogenous cannabinoids, synthesizing and metabolizing
enzymes that are active in both the central and peripheral
nervous system but also in many other organs. They mod-
ulate neuronal signaling and influence physiological pro-
cesses as sleep, mood and emotion, appetite, pain
perception and memory [9]. Two endogenous ligands of
the endocannabinoid system have been discovered: ana-
ndamide (AEA) and 2-arachidonoylglycerol (2-AG). Both
ligands are responsible for endocannabinoid signaling.
They are inhibited by their metabolizing enzymes, fatty
acid amine hydrolase (FAAH) and monoacylglycerol lipase
(MAGL), respectively. The most thoroughly investigated part
of the endocannabinoid system is the cannabinoid 1 and 2
(CB1 and CB2) receptor, which are widely distributed in the
gastrointestinal tract. They are found in the enteric nervous
system and epithelial cells. Particularly CB1 receptors are
expressed in the mucosa of the stomach and colon. In
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contrast, in non-inflamed human intestinal epithelium, CB2
receptors are absent or only weakly expressed [10,11]. CB2
receptors are mainly expressed by immune cells (neutro-
phils, plasma cells, activated macrophages and subsets of
B and T cells) and to a lesser extent by enteric neurons [11].
Activation of CB1 receptors leads to relaxation of smooth
muscle and to decreased gut motility and gut secretion.
Based on the current knowledge, the endocannabinoid sys-
tem as a whole is seen as a physiological entity that controls
gut homeostasis [12–14].
In addition, the endocannabinoid system has a role in
gut inflammation. The endocannabinoid system probably
serves as an endogenous gastrointestinal defense system
by affecting the regulation of the endogenous cannabi-
noids. Furthermore, inhibition of the metabolizing enzymes
(FAAH, MAGL) ensures ongoing activity of the endocanna-
binoids ligands (AEA and 2-AG) and CB receptors [15].
Activation of CB2 receptors causes suppression of inflam-
mation, resulting in improvement of mucosal healing in
murine colitis models [15–17]. So, potentially the endocan-
nabinoid system is a target for new therapies in IBD.
2.1. Role of cannabis on gastrointestinal inflammation
Recent evidence suggests that an anti-inflammatory effect
can be attributed to cannabis [14,18–20]. Cannabis contains
phytocannabinoids Δ9-tetrahydrocannabinol (THC) and can-
nabidiol (CBD). THC is known as a partial agonist of CB1 and
CB2 receptors. By activating CB receptors, THC suppresses
the production of pro-inflammatory cytokines and chemo-
kines and induces T cell apoptosis [15,20]. Δ9-tetrahydro
cannabinolic acid (THCA), a precursor of THC, has anti-
inflammatory activity on colon epithelial cell cultures, by
inhibiting IL-8 secretion [19]. Animal models show that can-
nabidiol is capable of modulating the endocannabinoid
system, through activation of CB1 by inhibiting FAAH [21].
However, because of the complex pathogenesis of IBD it
remains uncertain whether these anti-inflammatory effects
can be expected in humans as well.
3. Cannabis use among adult patients with IBD
The literature search identified 80 publications. Trials and sur-
veys on cannabis treatment for IBD were included. Only one
article focussed on adolescent and pediatric IBD patients.
Studies performed in adults were included as well. By hand-
searching, we finally included nine studies that evaluate canna-
bis treatment for adult patients with IBD [2–6,22–25] and one
for adolescent IBD patients (13–21 years of age) [8]. These
studies are shown in Table 1. In summary, a high prevalence
of cannabis use in adult and adolescent IBD patients is seen in
various countries [2–6]. Many patients report beneficial effects
of cannabis on IBD-related symptoms, as well as improvement
of the quality of life. Only one study group presented their
results between Crohn’s disease and ulcerative colitis patients
separately [22]. The ulcerative colitis-group consisted of two
patients so these patients were precluded from statistical ana-
lysis. More objective measurements were obtained with the
Crohn’s Disease Activity Index (CDAI) and Harvey Bradshaw
score, which significantly decreased after a period of cannabis
use [22–24]. This effect was not seen with cannabidiol [25].
A few side effects (panic attack, drowsiness, poor diet, lethargy,
and addiction) of cannabis were reported by patients [3].
However, the safety profile of cannabis and cannabidiol in the
treatment of IBD is poorly examined. Until now, cannabis in the
treatment of IBD seems promising.
Clear limitations of these studies were the low number of
included patients and the lack of standardization of the used
amount or the route of use of cannabis. No studies report an
endoscopic or histological evaluation of disease activity before
and after cannabis use. Therefore, the occurrence of mucosal
healing in human intestinal epithelium is unknown. Based on
current research no distinction can be made between the
effects of cannabis use on symptom relief in Crohn’s disease
or ulcerative colitis. Crohn’s disease is caused by transmural
inflammation instead of ulcerative colitis where the inflamma-
tion is limited to the mucosa, with the result that abdominal
pain is more frequently seen in Crohn’s disease. This distinction
could be relevant in further research. The high prevalence rates
of cannabis in IBD patients may be influenced by the recent
approval of medical marijuana by various states in the US and
Canada and also by increased attention in the press about the
beneficial effects of cannabis use for medical purposes.
4. The endocannabinoid system and the brain
The endocannabinoid system is not only involved in the gas-
trointestinal tract. The CB1 receptors are also widely distribu-
ted in the brain [26], which explains psychotropic properties as
described in cannabis use and abuse.
The endocannabinoid system is already present in the early
stages of brain development. During embryonal development of
the central nervous system, CB1 receptors and endogenous
cannabinoids (AEA and 2-AG) were detectable from 14 weeks
of gestation [27]. The endocannabinoid system is subject to
constant change from childhood to adolescence [27–29].
Therefore, cannabis use may have an adverse effect on brain
development, in case of early exposure, making cannabis
a controversial treatment option in children. Studies show that
Article highlights
● Incidence of pediatric IBD is rising, while conventional treatment in
many patients fails. Alternative treatment options have to be
explored.
● The endocannabinoid system is involved in gut homeostasis and can
be altered in an inflamed gastrointestinal tract.
● Questionnaires in adolescent and young-adult IBD patients report
relieve of IBD symptoms and improved quality of life when using
cannabis.
● Cannabis seems to have a potential immunomodulating effect on IBD
in murine colitis models.
● Preclinical data suggest a relevant role for endocannabinoid-
degrading enzymes, such as FAAH and MAGL. To what extent inhi-
bitors of these enzymes will cause decreased inflammation in
humans needs to be further investigated.
● Until there is sufficient data about the efficacy and safety profile of
cannabis, cannabis use needs to be actively discouraged in children
with IBD.
● Further research needs to focus on clinical response and evaluation of
mucosal healing due to cannabis or its purified ingredients.
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adolescents who frequently use cannabis in high doses have
a lower intelligence quotient (IQ) and reduced cognitive function
[30]. These effects are dose-dependent. Cessation of cannabis
use for 1 year does not result in full recovery of neurocognitive
functioning, especially when cannabis abuse was started in ado-
lescence [30,31]. The precise extent to which cannabis itself is
responsible for these effects is unknown. Lower social-economic
status and young age may influence the observed effect on
cognitive function [32].
THC is the primary psychoactive component of cannabis and
is able to affect brain function, by influencing cognitive func-
tions (learning, working memory and attention). Also neurophy-
siologic effects can occur, symptoms are: anxiety, paranoia and
psychiatric disorders (hallucinations, schizophrenia, and schizo-
phrenia-like psychotic disorders) [33,34]. A dose-response rela-
tionship is seen for these side-effects [35]. Regular cannabis use
in high dose before the age of 15 years is associated with
psychiatric disease and cognitive impairment [36].
5. Alternative agents influencing the
endocannabinoid system
Inhalation by smoking is the most frequently used mode of
application for cannabis consumption. Various side-effects and
risk for developing an addiction to smoking are well-known.
Therefore, other modes of application are urgently needed.
5.1. Cannabidiol oil
One of the treatment options is cannabidiol (CBD) oil. It is
important to acknowledge that CBD has low affinity for the
CB1 and CB2 receptors resulting in the absence of psycho-
tropic effects [21,37]. Therefore, CBD could be used safely
in children with IBD. However, a low dose of 20 mg/day of
CBD does not improve Crohn’s Disease Activity Index
(CDAI) of adults with IBD. This lack of effect on IBD symp-
toms can be explained by the fact that only a single com-
pound of cannabis (only CBD) is used. The authors also
suggested that the dose of CBD used might be too low to
be effective [25].
CBD has successfully been used in children for therapy-
resistant epilepsy (Dravet syndrome, Sturge-Weber syndrome
and Lennox-Gastaut syndrome), resulting in a significant
reduction in seizure frequency [38–40]. One hundred and
twenty children and young adults with Dravet syndrome
were included in a double-blind, placebo-controlled trial that
reported a decrease of median seizure frequency per month
from 12.4 to 5.9 (95% CI −41.1 to −5.4; P = 0.01) during the 14-
week treatment period [38]. This reduction was also seen in
a double-blind, placebo-controlled trial in 225 children and
adults with Lennox-Gastaut syndrome after 14 weeks of CBD
use (41.9% reduction in the 20 mg/kg CBD group (P = 0.005)
compared to 37.2% reduction in the 10 mg/kg CBD group (P =
0.002)) [40]. Four children with Sturge-Weber syndrome
showed a significant drop in seizure frequency after 8 weeks
of CBD treatment (average number of seizures per month
dropped from 10.7 to 7.7) [39]. The dose used was between
5 and 25 mg/kg/day orally. Kaplan et al. [39] started with a low
dose of CBD (5 mg/kg/day) and increased the dose by 5 mg/
kg/day per week as tolerated up to a maximum of 25 mg/kg/
day. Continuous doses of 10 mg/kg/day or 20 mg/kg/day were
used by Devinsky et al. [38,40]. More adverse effects were seen
when higher doses (20–25 mg/kg/day) of CBD were used:
somnolence, lethargy, behavioral problems, and increased sei-
zure activity. In addition, gastrointestinal adverse effects were
reported (diarrhea and vomiting) in 45% of the patients with
Dravet syndrome and in 16–26% of patients with Lennox-
Gastaut syndrome. After dose reduction, almost all adverse
effects resolved completely. 0.05–0,13% of the patients who
received CBD had to be withdrawn from the trial and discon-
tinued CBD administration due to adverse effects. Laboratory
values showed elevated liver enzymes in the CBD group
[38,40].
5.2. Sativex® (Nabiximols)
Sativex is an oromucosal plant-based cannabinoid spray. It is
mainly used in patients with multiple sclerosis where it is
able to relieve spasticity-related and neuropathic pain [41].
Also patients with chronic pain and post-operative pain
experience beneficial effects of Sativex. A meta-analysis on
the efficacy of cannabis-based medicines, including Sativex,
for pain management, showed a significant pain reduction in
chronic pain −0.61 (−0.78 to −0.43, P < 0.0001) [42]. This
spray contains both phytocannabinoids THC and CBD. Each
spray delivers a dose of 100 µL, containing 2.7 mg THC and
2.5 mg CBD. Sativex is generally well tolerated in patients
with multiple sclerosis-related spasticity; however, adverse
effects (such as anxiety, depression, constipation or diarrhea,
nausea, headache, dry mouth and somnolence) were com-
monly seen. These effects occurred in <10% of people and
usually appear during the first 4 weeks of treatment. More
serious effects (allergic phenomena, euphoria, psychosis,
panic, hallucinations, paranoia, suicidal ideation, memory
changes, and cognitive decline) were seen in <1% of people
[41]. No clinical trials have been performed on the efficacy
and safety of Sativex in patients with IBD.
5.3. Synthetic cannabinoids
Nabilone and Dronabinol are synthetic cannabinoids, both can
be administered orally. They mimic the effect of THC by acting
like CB receptor agonists and alter endocannabinoid signaling.
Both synthetic cannabinoids are approved for the treatment of
nausea and vomiting caused by chemotherapy in cancer
patients. Dronabinol is also approved as an appetite stimulant
in AIDS patients with weight loss. Nabilone was studied as an
alternative antiemetic in children with chemotherapy for can-
cer. The authors conducted a double-blind crossover study in
23 patients (aged from 1 to 17) with nabilone compared to
domperidone. In the nabilone group adverse effects were
more frequent, most commonly reported were drowsiness
(55%), dizziness (36%) and mood changes (14%). One patient
experienced hallucinations and withdrew from the trial. For
the other participants, adverse effects were thought to be
acceptable, they continued the treatment [43]. The effect of
nabilone and dronabinol on IBD symptoms and mucosal
inflammation has not been studied.
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5.4. FAAH and MAGL inhibitors
Another pharmacological strategy is to continue endocannabi-
noid signaling by inhibiting the metabolizing enzymes of ana-
ndamide (AEA) and 2-arachidonoylglycerol (2-AG), fatty acid
amine hydrolase (FAAH) and monoacylglycerol lipase (MAGL),
respectively, instead of direct activation of the CB receptors [44].
Selective inhibition of FAAH or FAAH blockade reduced damage
in experimental colitis models [14,45]. Also, MAGL inhibitors have
potential to counteract colitis and related systemic inflammation
[46]. So, both agents seem to have anti-inflammatory effects in
murine colitis models. For the time being there are no studies in
IBD patients with FAAH or MAGL inhibitors. Further research on
this topic is highly recommended because of the potential
immunomodulating mechanism.
6. Cannabis for medical purposes in children
Various effects of unintentional cannabis ingestion in children
have been described such as lethargy, ataxia, hypotonia,
mydriasis, tachycardia, hypoventilation and even respiratory
insufficiency [47]. Despite these adverse effects, would canna-
bis be a potential treatment option in pediatric IBD?
A recent descriptive cross-sectional study in Colorado,
described cannabis use in 99 pediatric patients (aged between
13 and 22 years) with IBD. Asmentioned in the introduction, 32%
of them used cannabis once during their lifetime while 9 % used
cannabis daily or almost daily. Most frequently medical purposes
for using cannabis were reported. Other reasons were to relax, to
relieve tension, to feel good and to have a good time with
friends. Participants used cannabis by smoking cigarettes or
ingesting edibles. However, 37% reported problems with con-
suming cannabis like craving and need for higher doses to reach
the same effect with the risk of developing addiction [8].
Pediatric IBD patients might benefit by relief in abdominal
pain, nausea, cramping, diarrhea, and improvement in appe-
tite and weight gain. These benefits are thought to be the
result of the effect of cannabis on the endocannabinoid sys-
tem and associated anti-inflammatory effect. However, the
mechanism of action of THC and cannabidiol is not fully
clarified, and well-designed clinical trials have not been per-
formed. As a result of symptom reduction without an actual
decrease of inflammation the IBD disease activity may be
underestimated by the patient, causing higher risks of serious
complications. Side-effects remain a problem in children as
well as concerns regarding brain development and cognition.
The mode of application is another important issue in chil-
dren. Smoking cannabis clearly is an unacceptable option in
children, because of the well-known negative effects of tobacco
smoking on health. Therefore, oral cannabidiol (like the oral
mucosal spray Sativex®) would be the preferred mode of appli-
cation. However, no studies on the pharmacokinetics and phar-
macodynamics of cannabidiol in children have been performed.
7. Conclusion
In summary, cannabis might potentially be a treatment option
in pediatric IBD in addition to conventional treatment. However,
to what extent cannabis acts as an immunomodulating agent
or just enhances a general feeling of well-being is unclear
currently. First, we support well-designed clinical trials to eval-
uate the efficacy and safety of oral cannabidiol in children with
IBD. These trials should include clinical response but also eval-
uate mucosal healing. For this specific age group, extra focus
has to be on the mode of application. Awaiting future research,
cannabis should actively be discouraged as a treatment mod-
ality in pediatric IBD.
8. Expert opinion
During the last decade, IBD in children has a rising incidence
and is accompanied by a high disease burden. Since conven-
tional therapies regularly are not sufficient, patients and parents
are looking for alternative treatment options. Currently, canna-
bis is of high interest in this field. Evidence suggests that
cannabis relieves IBD symptoms, improves quality of life and
to a lesser extent induces immunomodulating effects. However,
according to our literature research, we advise against the
prescription of cannabis in pediatric IBD. There are still a lot of
questions that need to be answered first.
The first key question is: what is the actual impact of
cannabis on inflammation in IBD? Preclinical data in murine
colitis models suggest that activation of CB receptors may lead
to mucosal healing by inhibiting the inflammatory reaction
[10,15]. Direct activation of the CB receptors may be caused by
inhalation of cannabis, using purified ingredients (such as CBD
and Sativex®) or synthetic cannabinoids (Nabilone and
Dronabinol). Moreover, continuous high levels of endogenous
cannabinoids will lead to activation of the CB receptors as
well. This effect can be achieved by inhibitors of the endocan-
nabinoid-degrading enzymes, FAAH and MAGL. So far, these
concepts are only tested in experimental trials. Whether acti-
vation of the CB receptors will realize mucosal healing in IBD
patients as well, need to be further investigated. Therefore, it
is important to evaluate disease activity endoscopically before
and after treatment with one of these agents.
Second key question is which agent would be most applic-
able in pediatric patients. As mentioned earlier smoking cigar-
ettes is no option in this category of patients. Purified ingredients
of cannabis, therefore, are of special interest in children. Most
experience exists with cannabidiol in children with therapy-
resistant epilepsy syndromes [38–40]. A major benefit of canna-
bidiol is the lack of psychotropic side-effects. Furthermore, CBD
seems well tolerated in this patient population, nevertheless
adverse events on behavior and gastrointestinal tract are
described as well. An anti-inflammatory effect of CBD on IBD in
humans is not proved yet. Experimental studies in animals have
shown promising results of immunomodulating effects of CBD
on colitis models [48]. An already available THC/CBD solution is
the oromucosal spray, Sativex®, which appears to be easily sui-
table for pediatric IBD patients, though a serious doubt about
sativex is the presence of THC in the solution. Due to the known
effects of THC on the central nervous system, psychotropic
adverse effect can be experienced by patients. More experience
in children exists with Nabilone, a synthetic cannabinoid.
Nabilone was used in children with chemotherapy-related nau-
sea as an antiemetic agent. However, serious side-effects like
hallucinations were experienced by one of the patients [43].
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Consequently, nabilone is likely not suitable for the treatment of
pediatric IBD. Furthermore, long-term effects of cannabidiol and
Sativex® are unknown. Chronic use of cannabis is associated with
impaired neurodevelopment outcome and addiction. Whether
these agents can cause these serious adverse effects as well is
unclear. The same is probably true for synthetic cannabinoids
through the equal mechanism of action in the endocannabinoid
system.
Knowledge about the endocannabinoid system is rapidly
expanding. With the increasing availability of legal cannabis
and medical marijuana around the world, the use of cannabis
for medical purposes is of high interest. There still are many
gaps in understanding these cannabinoid-based medicines
before they can be administrated to children, so further
research in this field is sorely needed. Currently, the main
benefit of cannabis for the treatment of IBD is improvement
of quality of life which is most likely caused by a general well-
being, a known effect of cannabis. To what extent this effect
can be attributed to reduced inflammation is uncertain.
Nowadays, the endocannabinoid system serves as an
encouraging therapeutic target for various abnormal condi-
tions of the gastrointestinal tract. The focus for the next five
years should be on the influence of the endocannabinoid
system on inflammation of the bowel. To evaluate whether
cannabis indeed can induce mucosal healing in the human
gut, endoscopic examination before and after treatment is
needed. The existing preclinical trials in murine colitis mod-
els report a major role for the endogenous cannabinoids
and its inhibitory enzymes. However, before implementa-
tion of these agents in the treatment of IBD patients further
preclinical research is required to better understand the
mechanism of action of the FAAH and MAGL inhibitors on
gastrointestinal inflammation.
There is an urgent need for larger clinical trials. Especially
elucidation of the efficacy and safety profile of cannabis and
the purified ingredients is required. In our opinion, well-
conducted trials on oral cannabidiol in pediatric IBD would
be of high interest. The research in this field is well underway,
but more time is needed before cannabis as part of IBD
treatment in children can be recommended.
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